Elixinol secures binding offer to exit US market, sharpening focus on Australian brands
Elixinol Wellness Limited (ASX: EXL) has announced that its wholly owned subsidiary, Elixinol LLC, has received a binding offer from Ananda Health, Inc. to acquire the company’s US business.
The offer provides for headline consideration of A$465,000, comprising upfront and deferred components that include a regulatory contingent payment and a revenue-based earn-out. The transaction is expected to reduce EXL’s exposure to the evolving US regulatory environment and sharpen its focus on its portfolio of Australian health and wellness brands.
The Board described the move as a “disciplined approach to risk management and capital allocation,” enabling the company to concentrate resources on the markets and brands with the strongest opportunities for profitable growth.
When big ASX news breaks, our subscribers know first
Why EXL is exiting the US market
The regulatory environment for hemp-derived cannabinoid products in the United States continues to evolve, creating uncertainty around the future manufacture, formulation and sale of certain products. Against this backdrop, EXL has made the strategic decision to divest its US operations.
Notably, the US business is not a material contributor to EXL’s current operating results and does not represent a significant portion of the company’s net assets. This positions the transaction as a focus-sharpening step rather than a distressed sale.
The EXL margin turnaround that preceded this divestment was itself driven by SKU rationalisation and a deliberate pullback from lower-margin channels, with gross margins climbing from 38% to 42% across FY25 as the business restructured around its strongest-performing Australian brands.
EXL has framed Ananda Health as the natural owner for the US business, describing it as an established US-based participant with vertically integrated manufacturing capabilities, market infrastructure and experience across the hemp and wellness sector.
CEO Commentary
“The decision to divest our US operations reflects the uncertain regulatory environment for hemp-derived products in the United States and our disciplined approach to managing risk and allocating capital,” said Natalie Butler, CEO of Elixinol Wellness.
“As an Australian-based company, we believe the interests of EXL shareholders are best served by reducing this regulatory exposure and focusing our resources on our portfolio of Australian health and wellness brands. Our priority remains driving profitable growth across our Australian portfolio.”
Breaking down the transaction terms
Under the binding offer, Ananda Health would acquire the assets associated with the Elixinol US business for a headline consideration of A$465,000, subject to adjustments and deferred consideration mechanisms contained in the Agreement.
| Component | Amount (A$) | Timing / Condition |
|---|---|---|
| Upfront on completion | $250,000 | At completion |
| Deferred payment | $20,000 | One month after completion |
| Purchase order reimbursement | $10,000 | Per agreement |
| Transition-related costs | $50,000 | Per agreement |
| Regulatory contingent payment | Potential $70,000 | If regulatory certainty achieved or no qualifying adverse change within 12 months |
| Revenue-based earn-out | Up to $65,000 | Based on net revenue over 12 months post-completion |
A key condition applies to the earn-out mechanism:
- The maximum earn-out becomes payable where net revenue generated by the business during the earn-out period exceeds US$1 million.
The transaction includes the assets, goodwill and intellectual property rights required to operate the Elixinol business in the United States. Importantly, EXL retains its rights to the Elixinol brand and associated intellectual property outside the territory transferred under the Agreement.
Completion, conditions and transition
Completion of the transaction is subject to customary conditions. These include:
-
Completion of due diligence
-
No material adverse change
-
Obtaining the required consents from the loan note holders that hold security over the US business
The company has flagged that the transaction will not proceed or complete unless those consents are obtained. The offer also contemplates transitional arrangements to support an orderly transfer, including operational, customer service, marketing and other support for up to six weeks following completion.
Completion is expected in early September 2026, subject to satisfaction or waiver of the conditions under the Agreement.
Understanding a strategic divestment
A divestment occurs when a company sells off a business unit, subsidiary or set of assets it no longer considers core to its strategy. Companies often exit non-core markets to reduce risk, simplify operations, and redirect capital and management attention toward stronger-performing areas.
The deal structure here uses deferred and contingent consideration, including an earn-out. Rather than paying the full amount upfront, the buyer links portions of the payment to future outcomes such as revenue performance and regulatory certainty. This aligns payment with how the business actually performs after completion, sharing risk between buyer and seller.
For EXL, stepping back from an uncertain regulatory market allows the company to concentrate on its Australian portfolio. That portfolio includes retail brands The Healthy Chef, Hemp Foods Australia and Mt Elephant, alongside ingredient brands Australian Primary Hemp and The Australian Superfood Co.
What this means for EXL shareholders
The transaction removes a layer of US regulatory overhang, simplifies the business, and reallocates resources toward markets and brands with the strongest opportunities for profitable growth. With the US business explicitly not a material contributor to operating results or net assets, the divestment centres on strategic focus rather than balance sheet impact.
Ananda Health, a vertically integrated health and wellness company based in Kentucky, has indicated its intention to provide continuity for the Elixinol US business and its customers.
The Priceline national rollout for The Healthy Chef, covering approximately 410 stores from July 2026 with a Stage Two expansion planned for early 2027, represents the most concrete near-term revenue event underpinning EXL’s Australian growth thesis.
Ananda Health Perspective
“We have great respect for what the Elixinol team have built, and our focus will be on ensuring continuity for the Elixinol business and its customers, while investing in the brand, product offering and customer experience to position Elixinol for its next phase of growth,” said Alex Nance, President of Ananda Health.
Looking ahead, EXL has reiterated its stated priority of driving profitable growth across its Australian vertically integrated healthy food business.
Don’t Miss the Next Consumer Sector Move on ASX
Big News Blast delivers FREE breaking ASX news straight to your inbox within minutes of release, complete with in-depth analysis so the work is already done. Join 20,000+ subscribers staying ahead of market-moving announcements across healthcare, consumer, tech and more. Click the “Free Alerts” button at StockWire X to start receiving alerts today.